Multiplexed bead-based assay for the simultaneous quantification of human serum IgG antibodies to tetanus, diphtheria, pertussis toxin, filamentous hemagglutinin, and pertactin.
Luminex (xMAP) method
diphtheria
enzyme-linked immunosorbent assay (ELISA)
multiplex immunoassay (MIA)
pertussis
tetanus
Journal
Frontiers in immunology
ISSN: 1664-3224
Titre abrégé: Front Immunol
Pays: Switzerland
ID NLM: 101560960
Informations de publication
Date de publication:
2023
2023
Historique:
received:
20
03
2023
accepted:
02
05
2023
medline:
23
6
2023
pubmed:
21
6
2023
entrez:
21
6
2023
Statut:
epublish
Résumé
Luminex bead-based assays offer multiplexing to test antibodies against multiple antigens simultaneously; however, this requires validation using internationally certified reference standards. Therefore, there is an urgent need to characterize existing reference standards for the standardization of multiplex immunoassays (MIAs). Here, we report the development and validation of an MIA for the simultaneous estimation of levels of human serum immunoglobulin G (IgG) antibodies for pertussis toxin (PT), filamentous hemagglutinin (FHA), pertactin (PRN), diphtheria toxoid (DT), and tetanus toxoid (TT). The MIA was assessed using a panel of human serum samples and WHO reference standards. The WHO reference standards were also studied for suitability in the MIA. Purified antigens (PT, FHA, PRN, DT, and TT) were coupled to the spectrally unique magnetic carboxylated microspheres. The method was validated in accordance with the United States Food and Drug Administration (US FDA), European Medicines Agency (EMA), and the International Committee of Harmonization Multidisciplinary (ICH M10) guidelines, and parameters such as precision, accuracy, dilutional linearity, assay range, robustness, and stability were assessed. Method agreements with commercially available IgG enzyme-linked immunosorbent assay (ELISA) assays were also evaluated. In addition, the study assessed the level of correlation between the IgG levels estimated by the MIA and the cell-based neutralizing antibody assays for PT and DT. We identified that an equimix of WHO international standards (i.e., 06/142, 10/262, and TE-3) afforded the best dynamic range for all the antigens in the MIA. For all five antigens, we observed that the back-fitted recoveries using the four-parameter logistic (4-PL) regression fits ranged between 80% and 120% for all calibration levels, and the percentage coefficient of variation (% CV) was < 20%. In addition, the difference in mean fluorescence intensity (MFI) between the monoplex and multiplex format was < 10% for each antigen, indicating no crosstalk among the beads. The MIA also showed good agreement with conventional and commercially available assays, and a positive correlation (> 0.75) with toxin neutralization assays for PT and DT was observed. The MIA that was calibrated in accordance with WHO reference standards demonstrated increased sensitivity, reproducibility, and high throughput capabilities, allowing for the design of robust studies that evaluate both natural and vaccine-induced immunity.
Sections du résumé
Background
Luminex bead-based assays offer multiplexing to test antibodies against multiple antigens simultaneously; however, this requires validation using internationally certified reference standards. Therefore, there is an urgent need to characterize existing reference standards for the standardization of multiplex immunoassays (MIAs). Here, we report the development and validation of an MIA for the simultaneous estimation of levels of human serum immunoglobulin G (IgG) antibodies for pertussis toxin (PT), filamentous hemagglutinin (FHA), pertactin (PRN), diphtheria toxoid (DT), and tetanus toxoid (TT).
Methods
The MIA was assessed using a panel of human serum samples and WHO reference standards. The WHO reference standards were also studied for suitability in the MIA. Purified antigens (PT, FHA, PRN, DT, and TT) were coupled to the spectrally unique magnetic carboxylated microspheres. The method was validated in accordance with the United States Food and Drug Administration (US FDA), European Medicines Agency (EMA), and the International Committee of Harmonization Multidisciplinary (ICH M10) guidelines, and parameters such as precision, accuracy, dilutional linearity, assay range, robustness, and stability were assessed. Method agreements with commercially available IgG enzyme-linked immunosorbent assay (ELISA) assays were also evaluated. In addition, the study assessed the level of correlation between the IgG levels estimated by the MIA and the cell-based neutralizing antibody assays for PT and DT.
Results
We identified that an equimix of WHO international standards (i.e., 06/142, 10/262, and TE-3) afforded the best dynamic range for all the antigens in the MIA. For all five antigens, we observed that the back-fitted recoveries using the four-parameter logistic (4-PL) regression fits ranged between 80% and 120% for all calibration levels, and the percentage coefficient of variation (% CV) was < 20%. In addition, the difference in mean fluorescence intensity (MFI) between the monoplex and multiplex format was < 10% for each antigen, indicating no crosstalk among the beads. The MIA also showed good agreement with conventional and commercially available assays, and a positive correlation (> 0.75) with toxin neutralization assays for PT and DT was observed.
Conclusion
The MIA that was calibrated in accordance with WHO reference standards demonstrated increased sensitivity, reproducibility, and high throughput capabilities, allowing for the design of robust studies that evaluate both natural and vaccine-induced immunity.
Identifiants
pubmed: 37342321
doi: 10.3389/fimmu.2023.1190404
pmc: PMC10278353
doi:
Substances chimiques
Pertussis Toxin
EC 2.4.2.31
pertactin
63GD90PP8X
Hemagglutinins
0
Antibodies, Bacterial
0
Immunoglobulin G
0
Diphtheria-Tetanus-acellular Pertussis Vaccines
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1190404Informations de copyright
Copyright © 2023 Rathod, Kadam, Gautam, Gumma, Marke, Asokanathan, Douglas-Bardsley, Hassell, Bhandare, Gupta, Parekh, Pujari, Rao, Sharma, Shaligram and Gairola.
Déclaration de conflit d'intérêts
Authors VR, LK, MG, PD, SB, SGu, SP, PP, HR, HS, US, and SGa are employees of the company Serum Institute of India Pvt. Ltd. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. The authors declare that this study received funding from Serum Institute of India Pvt. Ltd. The funder was involved in the study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Références
BMC Public Health. 2017 Feb 8;17(1):179
pubmed: 28178973
J Nat Med. 2018 Jan;72(1):32-42
pubmed: 29164507
Toxins (Basel). 2021 Jul 21;13(8):
pubmed: 34437379
mSphere. 2018 Aug 8;3(4):
pubmed: 30089645
Clin Vaccine Immunol. 2008 May;15(5):744-9
pubmed: 18321880
Infect Immun. 2004 Jan;72(1):615-20
pubmed: 14688147
Biologicals. 2019 Jan;57:9-20
pubmed: 30458978
Euro Surveill. 2022 Feb;27(8):
pubmed: 35209973
Clin Exp Vaccine Res. 2019 Jan;8(1):35-42
pubmed: 30775349
Biologicals. 1993 Mar;21(1):67-75
pubmed: 8217120
J Immunol Methods. 2016 Sep;436:29-33
pubmed: 27296810
Methods. 2019 Apr 1;158:33-43
pubmed: 30690077
Dev Biol Stand. 1996;86:207-15
pubmed: 8785950
Anal Biochem. 2011 Mar 15;410(2):310-2
pubmed: 21078286
Enferm Infecc Microbiol Clin. 2015 Jan;33(1):27-31
pubmed: 24216286
J Immunol Methods. 2009 Oct 31;350(1-2):142-9
pubmed: 19761770
J Med Microbiol. 2019 May;68(5):741-747
pubmed: 30990403
PLoS One. 2014 Dec 19;9(12):e115164
pubmed: 25525806
APMIS. 2010 Dec;118(12):968-72
pubmed: 21091778
Infect Immun. 1983 Jun;40(3):1198-203
pubmed: 6682833
Comp Clin Path. 2022;31(2):333-345
pubmed: 34840549
Infect Dis Ther. 2021 Dec;10(4):2539-2561
pubmed: 34476771
Pediatr Infect Dis J. 1997 Apr;16(4 Suppl):S97-102
pubmed: 9109164
Clin Vaccine Immunol. 2011 Apr;18(4):595-603
pubmed: 21325488
Int J Infect Dis. 2020 Jul;96:422-430
pubmed: 32387447
Biologicals. 2012 Nov;40(6):466-72
pubmed: 22898438
Pharmeuropa Bio. 2004 Jan;2003(2):35-68
pubmed: 14960262
Clin Vaccine Immunol. 2006 Feb;13(2):266-70
pubmed: 16467336
J Immunol Methods. 2008 Jun 1;335(1-2):79-89
pubmed: 18407287
Vaccines (Basel). 2016 May 10;4(2):
pubmed: 27171114
Clin Diagn Lab Immunol. 2002 Jul;9(4):872-6
pubmed: 12093688